MRC1 and leukemia: Unfortunately, acquired inhibition of the MMR pathway, allowing tolerance to O6mG lesions and chemoresistance, has been repeatedly documented in malignant glioblastoma, as well as in alkylation therapy-related leukemias [26–28,53–56]